Patients at risk

New England Journal of Medicine

Volumn 353, Issue 4, 2005, Pages 417-

  Drazen, Jeffrey M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG SAFETY; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; JC VIRUS; LEUKOENCEPHALOPATHY; NOTE; RISK;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK;

EID: 23644448596     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058123     Document Type: Editorial

References (4)

1. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
2. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
3. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
4. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005;353:414-6.